Fra­zier clos­es 12th fund in 30 years, with $617M to bet on cell/gene ther­a­py, Big Phar­ma spin­offs and more

The team at Fra­zier Health­care did a num­ber of deals that ex­em­pli­fied its wide-rang­ing strat­e­gy in 2019: Tachi Ya­ma­da worked with gene ther­a­py pi­o­neer Jim Wil­son to launch Pas­sage Bio; Mike Gal­latin sold Mavuphar­ma and its STING-tar­get­ed small mol­e­cule to Ab­b­Vie; and Bhaskar Chaud­huri flipped Ar­cutis to an IPO just months af­ter in­tro­duc­ing it to the world via a crossover round close to $100 mil­lion. They’re now kick­ing off 2020 with a new, big­ger fund that will give them fire­pow­er to do more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.